On July 18, 2022 Doma Biopharmaceutical reported that in the beautiful autumn of (October) 2021, Doma Biopharmaceutical officially entered into a partnership with BioBAY (Suzhou Biomedical Industrial Park) and initiated operations (Press release, Doma Biopharmaceutical, JUL 18, 2022, View Source [SID1234636140]). In the early summer (June) of 2022, Doma Biopharmaceutical proudly announced the successful closure of a 950 million yuan Series A financing round, setting sail for a transformative journey. Doma Biopharmaceutical is a collaborative venture founded by Biocytogen, China Life Private Equity Investment, PICC Capital, Suzhou Industrial Park Hefeng Capital, Taiping Healthcare Fund, and CMB International. With the robust support of our founding shareholders, we are poised to vigorously engage in innovative target drug development across a spectrum of cuttingedge biotechnology fields, including Dual-Payload ADC, oncolytic viruses, cell therapy, pet medications, diagnostic reagents, and AI.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Technological innovation has entered the 2.0 era, with scientists venturing into the realm of entrepreneurship. Converting scientific and technological breakthroughs into marketable products demands ceaseless exploration and innovation. As an open incubation platform for innovative biotechnology companies, we not only recognize the power of scientific innovation but also prioritize real clinical demands and market value. With access to startup funds and the technological prowess of our shareholders’ platforms, startups can quickly develop their products and technologies, devise strategies based on their professional strengths, and accelerate the creation of distinctive, globally competitive R&D pipelines. This fosters rapid company growth and enhances capital utilization efficiency, ultimately delivering favorable returns to our shareholders.
As an open, diverse, innovative, and efficient incubation platform for innovative biotechnology companies, Doma Biopharmaceutical aspires to collaborate with shareholders and entrepreneurs in pioneering the most cutting-edge domains of life sciences. By amalgamating state-of-the-art technologies, top-tier industry talent, and long-term capital, we endeavor to continually incubate world-class biotechnology innovators, introduce worldclass innovative medical products, and make significant strides in the treatment of diseases and the extension of human life.